Physician profile
George E Labrot
NPI 1447295357
$2,993.79
in general payments reported to CMS, 2019-2025
18 companies · $681 in 2025
The $681 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $158 · 2021: $61.11 · 2022: $289 · 2023: $734 · 2024: $719 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771 · Education: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,770.68 |
| Education | $364.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $827.74 | 2020-2025 | Wakix |
| Amgen INC. | $444.04 | 2019-2025 | Evenity, Tezspire |
| Regeneron Healthcare Solutions, INC. | $394.04 | 2022-2024 | Dupixent |
| Lilly USA, LLC | $203.30 | 2019-2025 | Zepbound, Mounjaro |
| Genzyme Corporation | $191.00 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.41 | 2023-2025 | Ofev |
| Inspire Medical Systems, INC. | $142.45 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $134.40 | 2019-2024 | Fasenra |
| Novo Nordisk INC | $105.66 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $94.95 | 2023 | |
| Glaxosmithkline, LLC. | $57.62 | 2023-2024 | Arexvy, Shingrix |
| Jazz Pharmaceuticals INC. | $54.11 | 2025 | |
| Pfizer INC. | $50.89 | 2024-2025 | |
| Axsome Therapeutics, INC. | $33.33 | 2024-2025 | Sunosi |
| Novartis Pharmaceuticals Corporation | $25.52 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.82 | 2023 | Quviviq |
| Circassia INC. | $15.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.96 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Labrot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.